for Cardiac Gene Therapy Vector Discovery and Development 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, today annou [...]
The notion of small molecules that detect dozens of cancers may sound like something out of a science-fiction novel. But for Christodoulou and her peers at Miroculus, it's more akin to a modern-day re [...]
Chemical engineer David Whitlock has made a splash in the media as of late, due to his lack of “splash”—as in the man hasn’t bathed in 12 years. The reason behind such a choice? David is working to d [...]
With FDA calling for non-invasive new tracking systems to accompany cell therapies, Bell Biosystems Inc. wants its Magnelle trackers to become the technology of choice. While the magnetic organelles' [...]
Covering Eltoprazine Treatment of Parkinson’s Disease and Alzheimer’s Disease Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product c [...]
Finnish hereditary disease diagnostics firm Blueprint Genetics plans to significantly expand its portfolio of clinical gene panel tests next year, and in the meantime has been pushing into new territo [...]
Symic Biomedical, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the selection of SB-061 as the company's [...]
Forgoing a shower, even for a day, makes some people want to hide from society and double up on the deodorant. For Dave Whitlock, this is simply life as usual.The chemical engineer and MIT grad decide [...]
On Thursday, November 6, scientists from ViewPoint Therapeutics published an article titled "Pharmacological chaperone for α-crystallin partially restores transparency in cataract models" in Science M [...]
Symic Biomedical, a clinical-stage biotherapeutics platform company developing compounds that target the extracellular matrix (ECM), today announced the treatment of the first patient in its Phase 1/2 [...]